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Amsterdam and 9) Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsAbstractTo provide better care for patients suspected of having Lyme borreliosis (LB) we founded the Amsterdam Multidisciplinary Lyme borreliosis
Center (AMLC). The AMLC reﬂects a collaborative effort of the departments of internal medicine/infectious diseases, rheumatology,
neurology, dermatology, medical microbiology and psychiatry. In a retrospective case series, characteristics of 200 adult patients referred
to the AMLC were recorded, and patients were classiﬁed as having LB, post-treatment LB syndrome (PTLBS), persistent Borrelia
burgdorferi sensu lato (s.l.) infection despite antibiotic treatment or no LB. In addition, LB, PTLBS and persistent B. burgdorferi s.l. infection
cases were classiﬁed as ‘deﬁnite,’ ‘probable’ or ‘questionable.’ Of the 200 patients, 120 (60%) did not have LB and 31 (16%) had a form
of localized or disseminated LB, of which 12 were classiﬁed as deﬁnite, six as probable and 13 as questionable. In addition, 34 patients
(17%) were diagnosed with PTLBS, of which 22 (11%) were probable and 12 (6%) questionable. A total of 15 patients (8%) were
diagnosed with persistent B. burgdorferi s.l. infection, of which none was classiﬁed as deﬁnite, three as probable and 12 as questionable. In
conclusion, in line with previous studies, the number of deﬁnite and probable (persisting) LB cases was low. The overall high number of
questionable cases illustrates the fact that it can sometimes be challenging to either rule out or demonstrate an association with a
B. burgdorferi s.l. infection, even in an academic setting. Finally, we were able to establish alternative diagnoses in a large proportion of patients.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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The ﬁrst two authors contributed equally to this article, and both
should be considered ﬁrst authorIntroductionLyme borreliosis (LB) is the most common tick-borne disease
in the northeastern part of the United States and in Europe in
temperate climate zones [1]. LB is caused by spirochetes of theMicrobiol Infect 2015; 21: 368.e11–368.e20
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.014Borrelia burgdorferi sensu lato (s.l.) group [2]. In the Netherlands,
the number of LB cases appears to be on the rise, from 100 per
100 000 inhabitants in 2005 to 134 per 100 000 inhabitants in
2009 [3]. Similarly, the number of visits to Dutch general
practitioners (GPs) for tick bites rose from 371 per 100 000 in
2001 to 446 and 564 in 2005 and 2009, respectively. Recently,
the Dutch ministry of health has asked for concerted action on
ticks and LB and has asked for the development of a nationwide
collaborative effort between medical and scientiﬁc institutes
focusing on LB to improve LB care and research in the
Netherlands.
Diagnosis and treatment of early localized LB in the
Netherlands is mostly done by GPs, but in cases of atypical
localized or disseminated disease, patients are often referred toious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Coumou et al. Patients suspected of Lyme borreliosis 368.e12medical specialists. According to international guidelines and
the recently updated Dutch national guideline, objective clinical
ﬁndings of early localized LB include erythema migrans (EM),
and objective clinical ﬁndings of disseminated LB include Borrelia
lymphocytoma, multiple EM, Lyme arthritis, Lyme carditis and
Lyme neuroborreliosis (LNB), among other, more rare mani-
festations [4–6] (http://www.diliguide.nl/document/1314).
Acrodermatitis chronica atrophicans (ACA) is usually referred
to as late LB. In case of an EM, which is pathognomonic for LB,
no further testing is recommended because EM can precede the
antibody response [7,8]. In contrast, serologic testing of anti-
bodies against B. burgdorferi s.l. in serum is required to conﬁrm
the diagnosis of disseminated LB. When appropriate, the diag-
nosis of disseminated LB can be further supported by evidence
from additional diagnostics, including culture and PCR of
B. burgdorferi s.l. on skin, synovial ﬂuid or cerebrospinal ﬂuid
(CSF) or suggestive histopathologic ﬁndings. Although the
prognosis of LB after recommended antibiotic treatment is
good and microbiological failure appears to be an infrequent
event, as discussed elsewhere [4], patients may experience
long-lasting and debilitating subjective symptoms despite rec-
ommended antibiotic treatment. This condition has been
referred to as post-treatment LB syndrome or post–Lyme
disease syndrome (PTLBS or PLDS) [4,6], and randomized
controlled trials did not show substantial or long-lasting bene-
ﬁcial effects of additional antibiotic treatment compared to
placebo [9–12].
With the available serologic tests, it is difﬁcult to differentiate
between active and past B. burgdorferi s.l. infection, and 4–8% of
the Dutch population has detectable antibodies against
B. burgdorferi s.l. [13]. Therefore, it is not recommended to test
patients with subjective symptoms without objective clinical
ﬁndings compatible with LB. Nonetheless, approximately 70%
of the serologic tests ordered by GPs are from such patients
[14]. To establish a diagnosis in a patient presenting with sub-
jective symptoms, with a history of tick bites and/or antibodies
against B. burgdorferi s.l.—previously treated or not treated for
LB—can be a challenge for physicians. On the one hand,
misdiagnosis of LB can lead to (multiple) antibiotic courses,
without effect, but with (serious) side effects or a delay in
identiﬁcation and management of the actual underlying cause of
the complaints [15]. On the other hand, when the clinical
presentation is less clear or when diagnostic tests are not
performed as or when they should be, a missed diagnosis could
result in prolonged or progressive illness.
Therefore, in an attempt to offer better care for patients
suspected of LB, we have initiated the Amsterdam Multidisci-
plinary Lyme Borreliosis Center (AMLC). At the AMLC,
various medical specialists, including infectious diseases spe-
cialists, neurologists, dermatologists and rheumatologists,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infecollaborate to establish a diagnosis in the referred patient—
either LB or an alternative diagnosis—and treat accordingly. In
this report, we describe the characteristics of the ﬁrst 200 adult
patients who were referred to the AMLC.Materials and methodsAMLC
The AMLC is located at the outpatient clinic of the Academic
Medical Center of the University of Amsterdam in the
Netherlands. The AMLC is open to referral of patients by GPs
from the Amsterdam region and medical specialist from all over
the Netherlands. Referrals were accepted—after being cen-
trally judged by an infectious disease specialist (JH or MvV)—
when there was a suspicion of LB, either based on the
described symptoms or signs or the results of previous diag-
nostic tests, or when the referring physician speciﬁcally
requested referral. On the basis of the provided clinical infor-
mation, patients were invited to the appropriate outpatient
clinic, i.e. the outpatient clinics of infectious diseases, neurology,
rheumatology or dermatology. In addition, the department of
medical microbiology was frequently consulted. Within each
department, there were one or two dedicated specialists who
were responsible for patients suspected of having LB. At all
AMLC outpatient clinics, information on tick bites, symptoms
compatible with LB, previous serologic testing and antibiotic
treatment was obtained, and a physical examination in search of
objective clinical ﬁndings compatible with LB was conducted. In
the majority of cases, a B. burgdorferi s.l. C6-EIA (IgM/IgG,
Immunetics) and upon indication an immunoblot (either IgM
and/or IgG) (Mikrogen) was performed by the department of
medical microbiology. Tests were considered positive on the
basis of the manufacturer’s cutoff or interpretation criteria.
Patients suspected of having LNB were seen by neurologists. At
the department of neurology, lumbar punctures were per-
formed when patients were suspected of having LNB. Patients
suspected of having Lyme arthritis were seen by rheumatolo-
gists. A synovial ﬂuid aspiration for a B. burgdorferi s.l. PCR
(Supplementary Information) was performed at the discretion
of the treating physician. Patients with skin lesions were seen at
the dermatology outpatient clinic, where skin samples were
taken for B. burgdorferi s.l. culture (Supplementary Information),
PCR or histology, upon indication. After this initial (multidis-
ciplinary) evaluation, it was determined whether the patient
required (additional) antibiotic treatment for LB. Antibiotic
treatment regimes, dosages and duration were in concordance
with the recent national guideline from the Dutch institute for
healthcare improvement (CBO) (http://www.diliguide.nl/
document/1314). Additional testing—such as blood tests andctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
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therapeutic interventions were left to the discretion of the
treating physicians. No systematic follow-up of patients was
present at the AMLC. However, follow-up was collected from
the documented clinical impression of the treating physician or
from the patient’s experience if documented. Further follow-up
was usually performed through the GP, who was given written
advice for further management.
Consecutive retrospective case series and
classiﬁcations
Case record forms from patients who were referred between
January 2011 and April 2013 were retrospectively reviewed
using standardized forms. Information on (previsit) diagnostic
test results, medical history, objective clinical ﬁndings, subjective
symptoms and previous treatment was recorded and analyzed
by SPSS software, version 21. On the basis of this information,
patients were classiﬁed into different categories: early localized
LB or disseminated LB if patients were not previously treated
(Table 1), and persistent B. burgdorferi s.l. infection or PTLBS if
patients were previously treated (Table 2). To address the
likelihood of a causal relationship between complaints and an
active or past B. burgdorferi s.l. infection, these four categories
were further classiﬁed as ‘deﬁnite,’ ‘probable’ and ‘questionable.’
Deﬁnite cases have a low risk, probable cases a low to inter-
mediate risk and questionable cases a high risk of being mis-
classiﬁed. Of note, alternative diagnoses were not found or were
considered unlikely in all of the case deﬁnitions mentioned
above. Finally, patients not fulﬁlling criteria for any of these
categories were classiﬁed as not having LB; in some of them, an
alternative diagnosis could be found or considered. All cases
were reviewed by two reviewers (EH and JC). If there was
disagreement between the two reviewers about the classiﬁca-
tion or if both could not classify the patient into a distinct
category, cases were classiﬁed by JH. Our retrospective analysis
is in accordance with the Academic Medical Center research
code, which is based on the Helsinki Declaration of 1975.
Deﬁnite early localized LB and disseminated LB. Cases with deﬁnite
LB included: (a) patients presenting with objective clinical
ﬁndings compatible with LB as described in national or inter-
national guidelines and supportive evidence from laboratory
tests, such as B. burgdorferi s.l. serologic tests, culture, PCR or
suggestive histopathologic ﬁndings [4,5] (http://www.diliguide.
nl/document/1314); (b) patients with neurologic ﬁndings
compatible with LNB, as described by the European Federation
of Neurological Societies guideline, with a pleocytosis in CSF
and positive intrathecal anti–B. burgdorferi s.l. IgG antibody in-
dex [16] (LNB cases with a duration of symptoms longer than 6
months were considered as late disseminated LB); and (c)Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatients presenting with objective clinical ﬁndings reminiscent
of LB, e.g. atypical skin lesions or a polyarthritis without
involvement of large joints, which were supported by positive
B. burgdorferi s.l. culture, PCR and/or suggestive histopathologic
ﬁndings.
Probable early localized LB and disseminated LB. Cases were
classiﬁed as probable LB when objective clinical ﬁndings remi-
niscent of LB were present in combination with B. burgdorferi s.l.
antibodies, or when neurologic ﬁndings were compatible with
LNB, with only a pleocytosis in CSF or a positive intrathecal
anti–B. burgdorferi s.l. IgG antibody index, in combination with
positive serologic tests for B. burgdorferi s.l. antibodies in serum.
Questionable disseminated LB. Cases were classiﬁed as ques-
tionable disseminated LB when no objective clinical ﬁndings
compatible with or reminiscent of LB were present in combi-
nation with B. burgdorferi s.l. antibodies in serum, as determined
by serologic tests. In addition, there was either a relation
between the onset of symptoms with a tick bite or a non-
documented EM or LB manifestation in the past.
Post-treatment LB syndrome. The classiﬁcation of probable PTLBS
was in line with the PLDS criteria from the Infectious Diseases
SocietyofAmerica (IDSA) guidelines [4].Wedid notdesignate this
as deﬁnite PTLBS because in our opinion, this diagnosis cannot be
deﬁnite. Cases classiﬁed as questionable PTLBS were identical to
probable PTLBS cases except that the preceding LB episode was
questionable, and cases were required to have positive serologic
tests for antibodies against B. burgdorferi s.l. We designated these
patients as having questionable PTLBS rather than medically un-
explained symptoms (MUS) because a relation with a previous
B. burgdorferi s.l. infection could not be fully excluded.
Persistent B. burgdorferi s.l. infection. Patients presenting with
objective clinical ﬁndings compatible with LB who had previ-
ously been treated with antibiotics were classiﬁed as having
deﬁnite (positive B. burgdorferi s.l. culture) or probable (positive
B. burgdorferi s.l. PCR and/or suggestive histopathologic ﬁndings)
persistent B. burgdorferi s.l. infection. Patients without objective
clinical ﬁndings but with subjective symptoms that progressed
over time despite previous recommended or inappropriate
antibiotic treatment for a documented LB episode were clas-
siﬁed as having questionable disease. In addition, questionable
persistent B. burgdorferi s.l. infection included patients present-
ing with progressive subjective symptoms despite previous
inappropriate antibiotic treatment for a questionable LB
episode in the past. We considered antibiotic treatment inap-
propriate when it did not meet guideline recommendations
[4,5] (http://www.diliguide.nl/document/1314), i.e. too short a
duration, insufﬁcient dosage, insufﬁcient frequency, use of aious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
TABLE 1. Overview of classiﬁcation used for diagnosis and probability of LB in patients suspected of LB not previously treated with
antibiotics
Probability Early localized LB Disseminated LBa
Deﬁnite  Typical EM
-or
 Objective clinical ﬁndings compatible with disseminated LBb
 Antibodies against B. burgdorferi s.l.c and/or supportive
laboratory evidenced
-or
 Atypical macular skin lesion
 Positive B. burgdorferi s.l.c PCR or culture from skin biopsy
 Objective clinical ﬁndings reminiscent of LBe
 Supportive laboratory evidenced
Probable  Atypical macular skin lesion
 History of tick bites
 Antibodies against B. burgdorferi s.l.c
 Neurologic ﬁndings suggestive of LNBf
 Antibodies against B. burgdorferi s.l.c
 Either a pleocytosis in CSF or positive intrathecal IgG AI
-or
 Objective clinical ﬁndings reminiscent of LBe
 Antibodies against B. burgdorferi s.l.c
Questionable  NAi  Subjective symptoms onlyg
 Antibodies against B. burgdorferi s.l.c
 Nondocumented LB episode in the pasth or a relation
between the onset of symptoms and a tick bite
LB, Lyme borreliosis; EM, erythema migrans; B. burgdorferi s.l., Borrelia burgdorferi sensu lato; CSF, cerebrospinal ﬂuid; AI, antibody index; LNB, Lyme neuroborreliosis; NA,
not applicable.
Patients not fulﬁlling these criteria were classiﬁed as no LB. Other evident explanations were excluded in patients fulﬁlling one of these criteria. Deﬁnite cases have a
low risk, probable cases a low to intermediate risk and questionable cases a high risk of being misclassiﬁed. For a more detailed description and explanation, see the
Material and Method section.
aIf duration of symptoms was less than 6 months, cases were classiﬁed as early disseminated LB. If duration of symptoms was more than 6 months or it was deﬁned as ACA,
which is usually classiﬁed as late LB, cases were classiﬁed as late disseminated LB.
bBased on Stanek et al. [5] (http://www.eucalb.com/), which is in line with the guideline from the Dutch institute for healthcare improvement (CBO)
(http://www.diliguide.nl/document/1314) and include Borrelia lymphocytoma,
multiple EM, Lyme arthritis, Lyme carditis and Lyme neuroborreliosis and ACA.
cAs determined in serum by a B. burgdorferi s.l. C6-EIA (IgM/IgG, Immunetics) and/or immunoblot (either IgM and/or IgG) (Mikrogen).
dB. burgdorferi s.l. culture or PCR and/or suggestive histopathologic ﬁndings.
eThese include atypical skin lesions, polyarthritis without involvement of large joints, conduction disorders of the heart other than AV-nodal conduction disorders or neurologic
symptoms which could be attributed to LB other than a meningoradiculitis, meningoencephalitis or polyradiculitis.
fBased on the European Federation of Neurological Societies guidelines by Mygland et al. [16].
gThese include nonspeciﬁc symptoms, such as widespread musculoskeletal pain (arthralgia or myalgia), paresthesia or complaints of cognitive impairment with or without fatigue.
hLB episode in the past reported by patient, not witnessed by a physician.
iWith clinical judgment, (repeated) serology and/or skin biopsies for PCR or culture it should be possible to distinguish a probable early localized LB from a non-LB related skin
manifestation.
CMI Coumou et al. Patients suspected of Lyme borreliosis 368.e14nonrecommended ineffective antibiotic or the simultaneous use
of supplements, such as calcium tablets, together with
tetracyclines.ResultsOf the patients referred to the AMLC, most were referred by
GPs (n = 162, 81%) (Table 3). Fatigue was the most reported
complaint, cited by 141 (71%) patients. Other common re-
ported symptoms included arthralgia, myalgia, paresthesia and
headache (Table 3). Skin lesions were the most reported
objective clinical ﬁnding, reported in 31 (16%) patients. More
than half of the patients (n = 108, 54%) had symptoms that were
present for more than 1 year at the time of presentation at the
AMLC; of these, only three had objective clinical ﬁndings that
were progressive over time. Before referral to the AMLC, for
the majority of patients, serologic testing was performed, and
approximately half of the patients had received antibiotic
treatment based on a suspicion of LB (Table 3).
A B. burgdorferi s.l. C6-EIA on serum as part of the AMLC’s
diagnostic assessment was done in 168 patients (84%) and wasClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infeconsidered positive in 66 tested sera (40% of tested sera)
(Supplementary Table 1). In the remaining 32 patients, the
treating specialist at the AMLC deemed additional testing un-
necessary on the basis of a low a priori chance of having LB or
previous serologic test results (Table 3). For many patients,
immunoblot analyses had been performed before referral to
the AMLC. Therefore, an immunoblot was performed in only
74 (37%) patients; of these, 28 (38% of tested sera) were
positive or indeterminate (Supplementary Table 1). A total of
20 PCRs on skin biopsy samples, synovial ﬂuid and CSF were
done to strengthen or conﬁrm the diagnosis of EM, ACA, Lyme
arthritis or LNB. In addition, 29 lumbar punctures to detect
speciﬁc intrathecal antibody production—by C6-EIA—and
pleocytosis in CSF were performed to conﬁrm or exclude LNB
(Supplementary Table 1). We also tested blood samples of 29
patients—either at the patients’ explicit request or because
patients had a reported positive PCR blood test from a com-
mercial laboratory before referral—using our clinically vali-
dated PCR—and found no positives (data not shown).
A graphical summary of the referral process and the analysis
at the AMLC is shown in Fig. 1A. On the basis of the criteria
shown in Tables 1 and 2, we concluded that 120 patients (60%)ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
TABLE 2. Overview of classiﬁcation used for diagnosis and probability of LB in patients suspected of LB previously treated with
antibiotics
Probability PTLBS Persistent B. burgdorferi s.l. infection
Deﬁnite  NAa  No resolution of previous documented LB episode
despite prior antibiotic therapyb
 Evidence of persistent infection (positive culture)
Probable  In line with Wormser et al.c
 Previous documented LB episoded
 Current presentation with only
subjective symptoms,e despite prior
recommended antibiotic therapyf
 Resolution of symptoms over time
 No resolution of previous documented LB episode
despite prior antibiotic therapyb
 Supportive evidence of persistent infection,
i.e. B. burgdorferi s.l. PCR and/or suggestive
histopathologic ﬁndings
Questionable  Questionable LB episode in the pastg
 Antibodies against B. burgdorferi s.l.h
 Current presentation only with
subjective symptomse despite prior
recommended antibiotic therapyf
 Resolution of symptoms over time
 Previous documented LB episoded
 Persisting subjective symptoms despite antibiotic therapyb
 No resolution or worsening of symptoms over time
 Antibodies against B. burgdorferi s.l.h
-or
 Questionable LB episode in the pastg
 Prior inappropriate antibiotic therapyf
 No resolution or worsening of symptoms over time
 Antibodies against B. burgdorferi s.l.h
LB, Lyme borreliosis; PTLBS, Post-treatment LB syndrome; B. burgdorferi s.l., Borrelia burgdorferi sensu lato.
Patients not fulﬁlling these criteria were classiﬁed as no LB. Other evident explanations were excluded in patients fulﬁlling one of these criteria. Deﬁnite cases have a low risk,
probable cases a low to intermediate risk and questionable cases a high risk of being misclassiﬁed. For a more detailed description and explanation, see the Material and
Method section.
aIn our opinion PTLBS cannot be deﬁnite.
bEither recommended or inappropriate treatment.
cFor more details, see Wormser et al. [4].
dPrevious objective clinical ﬁndings compatible with LB, which were witnessed by a physician and were diagnosed as LB.
eThese include nonspeciﬁc symptoms, such as widespread musculoskeletal pain (arthralgia or myalgia), paresthesia or complaints of cognitive impairment with or without fatigue.
fFor a description of recommended and inappropriate treatment, see Material and Methods.
gLB episode in the past reported by patient, not witnessed by a physician.
hAs determined in serum by a B. burgdorferi s.l. C6-EIA (IgM/IgG, Immunetics) and/or immunoblot (either IgM and/or IgG) (Mikrogen).
368.e15 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIdid not have LB (Table 4). In 43 of these patients, an alternative
diagnosis was established (Supplementary Table 2); for example,
seven patients had osteoarthritis. Patients were also diagnosed
with human immunodeﬁciency virus infection, polymyalgia
rheumatica or multiple sclerosis, among other diagnoses.
An active form of LB not previously treated with antibiotics
was diagnosed in 31 patients (16%), of which only 12 (6%) were
classiﬁed as deﬁnite LB, including ﬁve EM, two multiple EM, one
Lyme arthritis, one LNB and three ACA (Fig. 1B). In addition,
we classiﬁed six patients with probable LB, including three
patients with skin lesion or lesions—two atypical EM and one
atypical multiple EM—and three LNB cases supported by
pleocytosis in CSF and B. burgdorferi s.l. antibodies in serum (not
in CSF). The remaining 13 LB patients were classiﬁed as having
questionable LB. The most reported symptoms in patients with
questionable LB were fatigue, arthralgia, paresthesia, myalgia
and headache. In ten patients with questionable LB, a tick bite
related to the onset of the symptoms was reported, and in the
other three cases, the patients reported a nondocumented and
untreated EM in the past.
From the 200 referred patients, 104 had previously received
antibiotic treatment. Of these patients, 34 (17%) were diag-
nosed with PTLBS. We classiﬁed 22 patients (11%) as probable
PTLBS, meeting the criteria of the published case deﬁnition [4],Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectand 12 patients (6%) as having questionable PTLBS (Table 4).
Finally, 15 patients (8%) were classiﬁed as having persistent
B. burgdorferi s.l. infection, of which none was classiﬁed as def-
inite, three as probable and the majority (n = 12) as ques-
tionable. The three patients with probable persistent
B. burgdorferi s.l. infection included one patient who was diag-
nosed with a persisting EM—based on ongoing inﬂammation
observed by histopathologic examination of a skin section ob-
tained by skin biopsy—after antibiotic treatment for an EM that
had lasted for 2 months. However, B. burgdorferi s.l. culture and
PCR on skin samples were negative. The second patient was
diagnosed with persisting Lyme arthritis after previous antibi-
otic treatment for Lyme arthritis, supported by a B. burgdorferi
s.l. PCR on synovial ﬂuid. The third patient presented with
recurrent arthritis of the left ankle and IgG antibodies against
B. burgdorferi s.l. in serum. Before the onset of these symptoms,
the patient had been treated for an EM with doxycycline for 10
days, which was followed by a peripheral facial nerve paresis
that had resolved over time. These three patients received
antibiotic retreatment at the AMLC and clinically improved. In
the 12 patients with questionable persistent B. burgdorferi s.l.
infection, the most reported symptoms were fatigue (n = 8,
67%), arthralgia (n = 7, 58%), paresthesia (n = 6, 50%), headache
(n = 6, 50%) and myalgia (n = 4, 33%). In eight of the patientsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
TABLE 3. Characteristics, presenting symptoms and previsit
LB-related diagnostic assessment of 200 patients referred to
the Amsterdam Multidisciplinary Lyme Borreliosis Center
Characteristic Value
Gender
Male 82 (41%)
Female 118 (59%)
Age, years, median (range) 46 (18–80)
Referred by:
General practitioner 162 (81%)
Specialist 38 (19%)
Previous referrals to other specialists
for current complaints
118 (59%)
Symptoms (top 5)a
Fatigue 141 (71%)
Arthralgia 98 (49%)
Paresthesia 68 (34%)
Myalgia 54 (27%)
Headache 45 (23%)
Duration of symptoms
<6 weeks 16 (8%)
6 weeks–3 months 20 (10%)
3–6 months 23 (12%)
6–12 months 32 (16%)
More than 1 year 108 (54%)
No symptoms 1 (1%)
Tick bites (time since last tick bite) (n = 200)
No tick bite 96 (48%)
0–6 months 59 (30%)
6–12 months 5 (3%)
More than 1 year 39 (20%)
Unknown 1 (1%)
Previous B. burgdorferi s.l. serologyb 170 (85%)
Of which positive 127 (75%)
Previous B. burgdorferi s.l. PCR 5 (3%)
Of which positive 1 (20%)
Other nonrecommended testc 32 (16%)
Of which positive 27 (84%)
Antibiotic treatment 104 (52%)
Doxycycline 100 mg bid <1 monthd 78 (75%)
Doxycycline 100 mg bid >1 monthd 14 (13%)
Other antibiotic treatment <1 monthe 6 (6%)
Other antibiotic treatment >1 monthe 6 (6%)
Sums of percentages per group may exceed 100% due to rounding.
LB, Lyme borreliosis; B. burgdorferi s.l., Borrelia burgdorferi sensu lato; bid, twice
a day; ELISA, enzyme-linked immunosorbent assay; EIA, enzyme immunoassay.
aPatients could have reported multiple symptoms.
bEIA/ELISA or EIA/ELISA and immunoblot.
cOther nonrecommended B. burgdorferi s.l. tests include PCR on blood, dark-ﬁeld
microscopy live-blood analysis, lymphocyte transformation test and reduced
expression of CD57 on mononuclear cells. Tests were considered positive by the
(commercial) laboratory that performed the test.
dMay be combined with other antibiotic treatment.
eMay include: amoxicillin, atovaquone, azithromycin, ceftriaxone, ciproﬂoxacin, lari-
thromycin, metronidazole.
CMI Coumou et al. Patients suspected of Lyme borreliosis 368.e16with questionable persistent B. burgdorferi s.l. infection, previous
antibiotic treatment was regarded as inappropriate because
treatment was either too short or because patients had taken
calcium or other supplements, which could have lowered ab-
sorption of tetracyclines from the intestine. The remaining four
patients in the questionable persistent B. burgdorferi s.l. infection
category reported progressive subjective symptoms after rec-
ommended treatment for a documented LB episode, and no
alternative explanation was evident.
Antibiotic treatment was provided to 50 patients (25%) by
physicians at the AMLC, which included 27 of the 31 patients with
early localizedordisseminated LB.The remaining four patients had
already started with antibiotic therapy, initiated by the referring
physician. All patients with probable and questionable persistent
B. burgdorferi s.l. infection (n = 15) were treated with antibiotics.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfeFinally, eight patients retrospectively classiﬁed as having no LB or
PTLBS received antibiotic treatment at the AMLC.
Limited information on follow-up—several weeks to
months—was available for only 98 patients (49%), making it
insufﬁcient for a thorough analysis on follow-up. Nonetheless,
we compared the follow-up data from patients with objective
clinical ﬁndings compatible with or reminiscent of LB— i.e.
patients with deﬁnite or probable LB and probable persisting
B. burgdorferi s.l. infection—to that of patients with merely
subjective symptoms— i.e. questionable LB and questionable
persisting B. burgdorferi s.l. infection. In addition, we analyzed the
follow-up data of both probable and questionable PTLBS pa-
tients. Follow-up data were available from 17 of 21 patients
with objective clinical ﬁndings compatible with or reminiscent
of LB. All of these 17 patients improved. In contrast, in 17 of 25
questionable cases, follow-up data were available, and only eight
(47%) reported improvement. In addition, follow-up data were
available in 17 of 34 cases with PTLBS—because these were
usually referred back to the GP—and 15 (88%) of these 17
patients reported improvement.DiscussionIn this retrospective case series, we classiﬁed 200 patients who
were referred to our multidisciplinary LB referral clinic. The
relatively small number of patients with LB in our study may
reﬂect the societal concerns on LB diagnostics and treatment,
the difﬁculty of excluding LB from the differential diagnosis, a
lack of awareness of the current national guidelines by the
referring physicians or a lack of power to discriminate between
a past and active infection with current serologic tests. In
addition, the low number of active B. burgdorferi s.l. infections
among patients referred to the AMLC could be caused by
previous referral to (multiple) other medical specialists,
extensive testing on LB and antibiotic treatment before
consultation (Table 3). Notably, in 43 (36%) of the 120 AMLC
patients who did not have LB, an alternative diagnosis was
established (Supplementary Table 2). This illustrates there is a
serious risk of improper treatment and misdiagnosis in case of
referral or self-referral to ‘LB-literate’ doctors, who often di-
agnose these patients with ‘chronic Lyme disease’ and prescribe
prolonged nonrecommended antibiotic treatment [17,18].
A total of 31 patients (16%) were classiﬁed as having early
localized or disseminated LB. These observations are similar to
both reports from the United States [19,20], as well as a recent
study from a British LB referral clinic of 115 patients [21], in
which 23% of the patients suspected of having LB were thought
to have been infected with B. burgdorferi s.l. Another study on
LNB in Germany reported that of the 113 patients suspected ofctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
(a)
(b)
FIG. 1. (a) Graphical summary of 200 patients’ referral process to AMLC. *Pediatric infectious diseases are also part of AMLC, but only adults were
included in this study. (b) Deﬁnite (clear) and probable LB (shaded) cases (n = 18) at AMLC from 200 referred patients. ACA, acrodermatitis chronica
atrophicans; Diss. LB, both early and late disseminated LB; EM, erythema migrans; GP, general practitioner; LB, Lyme borreliosis; LNB, Lyme neu-
roborreliosis; PTLBS, Post-treatment LB syndrome.
368.e17 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIchronic LNB, one patient (<1%) had acute LNB, eight patients
(7%) had an acute LB—without LNB—and six patients (5%)
had residual symptoms after previously proven and treated
LNB or LB [22]. Collectively, this illustrates the low number ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatients with strong evidence of an active B. burgdorferi s.l.
infection in LB referral clinics. Indeed, the majority of LB pa-
tients in our study (n = 13) were classiﬁed as having ques-
tionable LB.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
TABLE 4. Classiﬁcation of LB in the 200 patients referred to the Amsterdam multidisciplinary LB center
Disseminated LB
No LB Early localized LB <6 months (early) >6 months (late) PTLBS
Persistent B.
burgdorferi s.l. infection
Probability (n [ 120) (n [ 7) (n [ 7) (n [ 17) (n [ 34) (n [ 15)
Deﬁnite 120 (100%) 5 (71%) 4 (57%)a 3 (18%)b NAc 0 (0%)
Probable NA 2 (29%) 2 (29%)d 2 (12%)e 22 (65%) 3 (20%)f
Questionable NA NA 1 (14%) 12 (70%) 12 (35%) 12 (80%)
Classiﬁcation is based on the criteria and deﬁnitions shown in Tables 1 and 2. For LNB criteria, see Material and Methods.
LB, Lyme borreliosis; B. burgdorferi s.l., Borrelia burgdorferi sensu lato; PTLBS, post-treatment LB syndrome; NA, not applicable; LNB, Lyme neuroborreliosis; MEM, multiple
erythema migrans; CSF, cerebrospinal ﬂuid.
aOne LNB, one Lyme arthritis and two MEM.
bThree ACA.
cSee Tables 1 and 2.
dOne LNB, with pleocytosis but without B. burgdorferi s.l. antibody production in CSF, and one MEM.
eTwo late LNB, with pleocytosis but without B. burgdorferi s.l. antibody production in CSF.
fCases are described in text.
CMI Coumou et al. Patients suspected of Lyme borreliosis 368.e18Patients classiﬁed as having questionable LB presented with
subjective symptoms only. In general, these subjective symp-
toms have no predictive value for LB. However, patients with
questionable LB in our study had positive B. burgdorferi s.l.
serologic tests in combination with either a relation between
the onset of symptoms with a tick bite or a nondocumented EM
or LB manifestation in the past. In addition, after careful ex-
amination by multiple specialists at the AMLC, another expla-
nation could not be demonstrated. It could be debated whether
instead of questionable LB we could have designated these
patients as having possible, improbable or dubious LB.
Regardless, on the basis of the CBO guideline, which recom-
mends treating cases with a low a priori chance for LB and
positive B. burgdorferi s.l. serologic tests, we chose to treat these
patients with antibiotics. We do not recommend that GPs and
physicians outside LB referral clinics follow our approach, and
we emphasize that careful exclusion of other causes and
consultation of other specialists is of paramount importance for
this patient category. We discussed with these patients that if
the recommended antibiotic therapy had no long-lasting effects,
LB was unlikely to be the cause of their symptoms. The beneﬁt
of our approach might be that both physician and patient can
focus on additional investigations in search of the etiology
or—perhaps more often—adequate management of MUS
when antibiotics did not have any effects. On the contrary,
when symptoms did resolve, a positive response to antibiotics
does not necessarily mean the patient was infected with
B. burgdorferi s.l. because a placebo effect, an immunomodula-
tory effect of the antibiotic or the mere effect of time could be
alternative explanations.
Another 34 (17%) of the referred patients were diagnosed
with PTLBS, of whom 12 were classiﬁed as questionable PTLBS,
since a relation with preceding B. burgdorferi s.l. infection could
not be ignored because of B. burgdorferi s.l. serology and no
evident alternative cause. However, an active infection withClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfeB. burgdorferi s.l. was considered highly unlikely. The symptoms
of the PTLBS patients are nonspeciﬁc and share similarities with
those of chronic fatigue syndrome, ﬁbromyalgia or MUS. The
treatment for patients diagnosed with PTLBS and MUS is similar
and does not include antibiotic treatment, but an individualized
approach is necessary to achieve acceptance and improvement
of quality of life in which the GPs plays a central role. Special-
ized MUS centers can provide multidisciplinary education and
advice or even cognitive therapy. Indeed, the AMLC internally
referred four patients to a psychiatrist with expertise in the
management of MUS. Recently, after the completion of this
study, the AMLC begun a collaboration with a MUS center at
the VU University Medical Center Amsterdam.
Finally, of the 15 cases of persistent B. burgdorferi s.l. infec-
tion, none was classiﬁed as deﬁnite and three were classiﬁed as
probable. The absence of deﬁnite persistent B. burgdorferi s.l.
infection cases and the low number of probable persistent
B. burgdorferi s.l. infection cases in our study is not unexpected
because a persistent B. burgdorferi s.l. infection after recom-
mended antibiotic treatment appears to be rare [4,23]. It is also
possible that complaints, if caused by an active B. burgdorferi s.l.
infection, are the result of a reinfection rather than a persistent
infection [24]. The 12 patients diagnosed with questionable
persistent B. burgdorferi s.l. infection had subjective symptoms
only, similar to patients diagnosed with questionable LB, with
the difference that they had received (inappropriate) antibiotic
treatment for a prior (questionable) LB episode and that their
symptoms were progressive over time (Table 2). Although
partially against published trials [9–12], and not recommended
by the IDSA guidelines [4], retreatment of questionable
persistent B. burgdorferi s.l. infection cases, especially those in
patients who had had received prior inappropriate treatment, is
in accordance with recommendations from the recent Dutch
national guidelines (http://www.diliguide.nl/document/1314) and
was the result of a compromise between physician and patient.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e11–368.e20
368.e19 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIAs we did with questionable LB patients, we discussed the pros
and cons of antibiotic treatment in patients with questionable
persistent B. burgdorferi s.l. infection. Speciﬁcally, we discussed
the fact that if their LB did not respond to antibiotic therapy, a
persistent B. burgdorferi s.l. infection was unlikely, and we dis-
cussed the option of treatment for MUS. Our classiﬁcation
‘questionable persistent B. burgdorferi s.l. infection’ might be
useful to describe the patient population in a (tertiary) Lyme
clinic. However, because the risk of misclassifying these patients
is high, such cases should only be used with caution for future
clinical or research purposes. Furthermore, this classiﬁcation
should not be confused with ‘chronic Lyme disease,’ which is a
misnomer describing patients with chronic subjective symp-
toms that are attributed to LB but that is in fact a heterogenous
group, as previously described [16,25].
Although incomplete and limited, our follow-up analysis
showed that antibiotic treatment resulted more often in
improvement in patients with objective clinical ﬁndings compat-
iblewith or reminiscent of LB compared to patients inwhomonly
subjective symptoms were present. In future studies, we will
strive for more accurate and complete follow-up over a longer
period of time, which will be facilitated in the near future by a
multicenter prospective study assessing the risk of, and the risk
factors for, developing persisting symptoms after treated LB. In
addition, once the number of well-deﬁned (deﬁnite and probable)
LB cases increases, we will perform multiple logistic regression
analysis to identify negative and/or positive predictors for LB.
To conclude, LB is an infectious disease to which speciﬁc
objective clinical ﬁndings have been attributed. However, LB is
invariably linked by many to a wide range of subjective symp-
toms, limited diagnostic test options and poor treatment op-
tions and outcomes. This affects the use of diagnostic tests for
and treatment of LB by physicians. In the current study, we
used established criteria and also proposed new criteria to
categorize patient populations at LB referral centers. Using
these criteria, we show that we were able to exclude LB in
many cases, to establish alternative diagnoses for a signiﬁcant
group of patients and to categorize most of the patients into
distinct classiﬁcations. Using the currently available diagnostic
tests, for some patients—especially questionable LB and
questionable persisting B. burgdorferi s.l. infection cases— it is
difﬁcult to determine whether these patients indeed had a
symptomatic B. burgdorferi s.l. infection. Future tests might be
able to better distinguish between past and active B. burgdorferi
s.l. infections and could thus partially resolve these issues and
guide antibiotic treatment. Until these tests are developed,
validated and widely available, physicians with both experience
with and afﬁnity for LB should determine the likelihood of an
active infection with B. burgdorferi s.l. in each individual patient.
The beneﬁts of a tertiary referral center for LB—such as theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectAMLC—are that this evaluation is done in a multidisciplinary
and systematic manner by experienced specialists, it can initiate
and engage in basic and clinical research on LB and it will un-
cover alternative diagnoses. Thus, tertiary LB referral centers
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